The scientific article cited by Health Minister Marcelo Queiroga this Tuesday morning (4) to contest Anvisa’s approval of the vaccine for children between 5 and 11 years old, in fact, attests to the effectiveness of the immunizing agent.
In an interview, Queiroga mentioned a study published in the New England Journal of Medicine on childhood vaccination against Covid in an attempt to challenge Anvisa’s decision to release the immunizing agent for children on an emergency basis.
“Have you read the study that came out in the New England Journal of Medicine about the 5- to 11-year vaccine? So, you have to see it,” the minister told reporters.
“Read the document that is there. If we are going to make decisions based on randomized studies, on better quality science, or if we are going to make decisions only based on expert opinion. And sometimes they are specialists who are not so specialists”, continued the minister when using the study to contradict the approval of Anvisa, which heard about 1,600 people during the process of evaluating the child immunization agent.
The New England Journal of Medicine study shows, however, that there is a 90.7% efficacy of the vaccine for preventing Covid-19 in children aged 5 to 11 years for at least seven days after the second dose and for at least 70 days.
In the presentation of the results, the study says that the childhood immunizer “showed a favorable safety profile”, and that “no serious adverse events related to the vaccine were observed”.
The study also says that, after applying the infant dose, “children aged 5 to 11 years showed a neutralizing antibody response at concentrations similar to those observed in adolescents and adults aged 16 to 25 years, meeting the proposed criteria for demonstrating non-inferiority” .
Reference: CNN Brasil
